Being overweight during teenage years may increase risk of bowel cancer
the ONA take:
New research indicates that obesity during one's teenage years could greatly increase that chances of developing bowel cancer by middle age.
The correlation between adult obesity and increase bowel cancer risk, but less is known about how being very overweight in your teenage years can impact later bowel cancer risk.
Researchers led by Dr Elizabeth D Kantor, of the Harvard School of Public Health, revised the health records of approximate 240,000 Swedish men who had entered military service from 1969 through 1976. The men were all 16 to 20 years old at the time of their military conscription.
At enlistment, Swedish men are given a health check which includes measurements for height and weight, as well as ESR levels.
These men were then monitored for bowel cancer until 2010 via national cancer registry data. Most of the men (approximately 81%) were considered of standard weight at conscription, some (5%) were classified as overweight, and a 1% were labeled as obese.
Over the 35-year cancer monitoring period, 885 of the 240,000 men developed bowel cancer. Overweight individuals (BMI ranging from 27.5 to just under 30 kg/m2) were found to be twice as likely to develop bowel cancer as their fellow soldiers of average (BMI ranging 18.5 through 25 kg/m2) weight.
Obesity during the teenage years, classified by a BMI of over 30 kg/m2, was associated with a 2.38 times higher risk of later bowel cancer development. ESR was also found to be a factor; those men with a ESR of 15+ mm/hr had a 63% greater chance of developing bowel cancer than those with a low ESR of less than 10 mm/hr.
Further studies are needed, as this research was an observational study, but inflammation and weight status during adolescence do appear to be linked to a later increased risk of bowel cancer development.
Obesity during one's teenage years could greatly increase that chances of developing bowel cancer by middle age.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|